Official Title
COVID-19 and Childhood Cancer - Diagnostic Delay, Survival, and COVID-19 Susceptibility
Brief Summary

The investigators will first examine the impact of the COVID-19 pandemic on childhoodcancer patients in Sweden and Denmark, both regarding susceptibility to severe COVID-19among long-term childhood cancer survivors, and, for those diagnosed with childhoodcancer during the pandemic, whether the path through primary care to cancer diagnosis aswell as short-term survival has changed. Second, the investigators will study childhoodcancer incidence before, during and after the pandemic with the particular aim to testthe hypothesis regarding an infectious disease etiology for acute lymphoblastic leukemia.

Detailed Description

Not Provided

Active, not recruiting
COVID-19
Childhood Cancer
Childhood Leukemia, Acute Lymphoblastic
Eligibility Criteria

Inclusion Criteria for studying severe COVID-19 among childhood cancer survivors:

- Childhood cancer cases (age 0-19) diagnosed from 1971 in Sweden and Denmark who were
alive five years after diagnosis

- Two different comparisons groups: five age- and sex-matched comparisons for each
childhood cancer survivor as well as all siblings of the childhood cancer survivors.

- All childhood cancer survivors, matched comparisons, and siblings of the survivors
should be 20+ at the start of 2020.

Inclusion Criteria for studying childhood cancer incidence and survival and number of
contacts with healthcare before the childhood cancer diagnosis:

- All children (age 0-19) diagnosed with cancer from 2015 in Sweden and Denmark

Exclusion Criteria:

- No exclusion criteria

Eligibility Gender
All
Eligibility Age
Minimum: 0 Years ~ Maximum: 19 Years
Countries
Sweden
Locations

Karolinska Institutet
Stockholm, Sweden

Giorgio Tettamanti, PhD, Principal Investigator
Karolinska Institutet

Karolinska Institutet
NCT Number
Keywords
Childhood Cancer
Childhood Cancer Incidence
Childhood Cancer Survival
Childhood Leukemia, Acute Lymphoblastic
cohort study
Register Study
MeSH Terms
COVID-19
Precursor Cell Lymphoblastic Leukemia-Lymphoma